MarginsXMarginsX
Home › Markets › Health Care › CATX

Perspective Therapeutics Inc. (CATX)

CATX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9238
-2.05% on the day
Market cap
$111.6M
Micro cap
Revenue · 2023
$1.4M
Prior year not contiguous
Net income · 2023
-$46.5M
-3243.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/728387/000143774924009696/0001437749-24-009696-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerCATX on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000728387
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$1.4M
Net income-$46.5M
Operating income-$40.9M
Net margin-3243.2%
Operating margin-2855.0%
Revenue growthNo prior-year revenue to compare
Cash$9.2M
Total assets$97.9M
P/E (computed)Net income was not positive
P/S (computed)77.8×

Warning signs

Cash runway
4.6 months
$41.0M cash at September 30, 2026
Share count, 1 year
+62.4%
2025-11-06 to 2026-11-04 · +330.4% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$1.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$41.0M cash; operating cash flow -$27.0M a quarter.Report 2026-09-30
Shares outstanding120,758,815 (2026-11-04); 74,337,990 a year earlier; 280,571,026 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-04
Reverse splits, 3 years1; latest 1-for-10 on 2024-06-17Source 2024-06-17
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-02-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWithumSmith+Brown, PC, San Francisco, California, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $42K, sold $1.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed-$32.4M-$31.4M$41.0M$1.6MNeeds four quarters10-Q 2026-11-09
Q4 2026
2026-06-30
Not filed-$26.8M-$20.6M$48.5M$1.6MNeeds four quarters10-Q 2026-11-09
Q3 2026
2026-03-31
Not filed-$26.2M-$31.5M$54.0M$1.6MNeeds four quarters10-Q 2026-11-09
Q2 2026
2025-12-31
Not filed-$37.5M-$24.7M$30.6M$1.6MNeeds four quarters10-K 2026-03-16
Q1 2026
2025-09-30
Not filed-$26.0M-$16.3M$26.8M$1.6MNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-06-30
Not filed-$21.5M-$20.0M$28.8M$1.7MNeeds four quarters10-Q 2026-11-09
Q3 2025
2025-03-31
Not filed-$18.2M-$21.6M$44.4M$1.7MNeeds four quarters10-Q 2026-11-09
Q2 2025
2024-12-31
Not filed-$40.2M-$26.6M$61.6M$1.7MNeeds four quarters10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-03
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-16

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+11.9%
1 month-58.6%
3 months-69.7%
Year to date-65.8%
1 year-54.6%
From 52-week high-83.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M
IMUXImmunic Inc.$7.23-3.86%$114.8M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
ADAGAdagene Inc.$1.60-6.43%$105.7M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier